Rasagilin
Rasagilin
Klass: A
Visa all info
Skriv ut
Kontakta oss
Produkter
Visa alla produkter
AZILECT, Rasagilin Glenmark, Rasagilin Krka, Rasagilin ......
AZILECT, Rasagilin Glenmark, Rasagilin Krka, Rasagilin STADA, Rasagiline Accord, Rasagiline Amneal, Rasagiline Bluefish, Rasagiline Mylan, Rasagiline SandozATC-koder
N04BD02
N04BD02Substanser
rasagilin, rasagilinmesilat, rasagilintartrat
rasagilin, rasagilinmesilat, rasagilintartratSammanfattning
Kliniska studier som jämfört rasagilin (1 mg/dag) med placebo har inte kunnat påvisa könsskillnader i effektivitet, varken vid monoterapi eller som tilläggsbehandling.
Vissa studier rapporterar en ökad risk för impulskontrollstörning hos män jämfört med kvinnor vid behandling med parkinsonläkemedel, medan andra studier inte visar några könsskillnader. Kliniska studier av rasagilin utförda av läkemedelsföretaget har inte funnit könsskillnader i säkerhetsprofilen av rasagilin.
Background
The reported incidence and prevalence of Parkinson’s disease (PD) is slightly higher in men than in women. It seems that men develop PD earlier in life compared to women. Several possible explanations behind these sex differences have been suggested; the protective role of estrogens in premenopausal women, and different profiles of risk factors (environmental and/or genetic). Sex differences in clinical presentations of PD have also been reported. Since the activities of daily living might differ between men and women with PD, different treatment strategies can be recommended to men and women with PD [1]. Visa hela bakgrundstexten
Pharmacokinetics and dosing
No differences in rasagiline pharmacokinetics have been reported between men and women and no sex differentiation in dosing has been recommended by the pharmaceutical company [7].
Effects
A double-blind randomized monotherapy trial conducted by the pharmaceutical company, comparing rasagiline 1 mg/day with placebo, could not detect any differences in effectiveness based on patient’s age or sex. Similarly, no trials of rasagiline as adjunctive therapy,......
Försäljning på recept
Visa hela försäljning på recept
Fler män än kvinnor hämtade ut tabletter innehållande rasagilin (ATC-kod N04BD02) på recept i Sverige år 2019, totalt 2 224 män och 1 258 kvinnor. Det motsvarar 0,4 respektive 0,3 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70-84 år hos båda könen. I genomsnitt var tabletter innehållande rasagilin två gånger vanligare hos män [8].
Referenser
Visa referenser
Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.
Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-73.
Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18:207-9.
Carrière N, Kreisler A, Dujardin K, Destée A, Defebvre L. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients]. Rev Neurol (Paris). 2012;168:143-51.
Poletti M, Logi C, Lucetti C, Del Dotto P, Baldacci F, Vergallo A, Ulivi M, Del Sarto S, Rossi G, Ceravolo R, Bonuccelli U. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. 2013;33(5):691-4.
Garcia-Ruiz, P J Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840-4.
Azilect (rasagiline mesylate). DailyMed [www]. US National Library of Medicine. [updated 2019-04-22, cited 2019-11-07].
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
- Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.
- Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-73.
- Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18:207-9.
- Carrière N, Kreisler A, Dujardin K, Destée A, Defebvre L. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients]. Rev Neurol (Paris). 2012;168:143-51.
- Poletti M, Logi C, Lucetti C, Del Dotto P, Baldacci F, Vergallo A, Ulivi M, Del Sarto S, Rossi G, Ceravolo R, Bonuccelli U. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. 2013;33(5):691-4.
- Garcia-Ruiz, P J Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840-4.
- Azilect (rasagiline mesylate). DailyMed [www]. US National Library of Medicine. [updated 2019-04-22, cited 2019-11-07].
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
Uppdaterat
Litteratursökningsdatum 11/7/2019
Litteratursökningsdatum 11/7/2019